breast-cancer

Blocking estrogen precursor transport into breast cancer cells suppresses tumor growth without harming normal cells.

New SOAT (SLC10A6) inhibitors (compounds 12 and 24) markedly reduced DHEAS uptake in MCF-7 breast cancer cells, decreasing intracellular estradiol synthesis and suppressing estrogen-dependent proliferation without cytotoxicity to normal cells. SOAT is an upstream regulator of intracrine estrogen…

Blocking estrogen precursor transport into breast cancer cells suppresses tumor growth without harming normal cells.

Key Findings

New SOAT inhibitors (compounds 12 and 24) reduced DHEAS uptake
Inhibition decreased intracellular estradiol synthesis and estrogen-dependent proliferation
No cytotoxicity to normal cells
SOAT is a critical upstream regulator of intracrine estrogen in ER-positive breast cancer
Compounds 12 and 24 are promising preclinical candidates

Implications

SOAT inhibitors could provide a novel strategy for postmenopausal ER-positive breast cancer, particularly those resistant to aromatase inhibitors.

Caveats

In vitro cell line study; abstract-only. In vivo validation and clinical translation needed. SOAT expression varies across patients.

Source: Scientific reports — 2026-04-10

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.

Blocking estrogen precursor transport into breast cancer cells suppresses tumor growth without harming normal cells.

Key Findings

Implications

Caveats

Read more

Landmark DCIS trial, CRC microbiome & AML combos

Colorectal Cancer Microbiome Discovery Platform

GBM Tumor Microenvironment Drug Target Atlas

BET Inhibitor Target Selectivity Database